

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

KERYX BIOPHARMACEUTICALS INC  
Form SC 13G  
February 14, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)  
(Amendment No. \_\_\_\_)\*

Keryx Biopharmaceuticals, Inc.  
(Name of Issuer)

Common Stock, \$.001 par value per share  
(Title of Class of Securities)

492515101  
(CUSIP Number)

December 31, 2006  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-----  
CUSIP No. 492515101  
-----

13G

-----  
PAGE 2 OF 5 PAGES  
-----

- 1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Chilton Investment Company, LLC

87-0742367  
-----

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

(a) [ ]  
(b) [X]

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

State of Delaware

	5.	SOLE VOTING POWER	
			2,266,248
NUMBER OF	6.	SHARED VOTING POWER	
SHARES			0
BENEFICIALLY	7.	SOLE DISPOSITIVE POWER	
OWNED BY			2,266,248
EACH	8.	SHARED DISPOSITIVE POWER	
REPORTING			0
PERSON			
WITH			

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,266,248

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

[ ]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.2%

12. TYPE OF REPORTING PERSON (See Instructions)

IA

CUSIP No. 492515101

13G

PAGE 3 OF 5 PAGES

Item 1(a). Name of Issuer.  
Keryx Biopharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices.  
750 Lexington Avenue, New York, NY 10022

Item 2(a). Names of Person Filing.  
Chilton Investment Company, LLC

Item 2(b). Address of Principal Business Office or, if None, Residence.  
1266 East Main Street, 7th Floor  
Stamford, CT 06902

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

Item 2(c).                    Citizenship.  
                                  State of Delaware

Item 2(d).                    Title of Class of Securities.  
                                  Common Stock, \$.001 par value

Item 2(e).                    CUSIP Number.  
                                  492515101

Item 3.   If This Statement is Filed Pursuant to Rule 13d-1(b), or  
          13d-2(b) or (c), Check Whether the Person Filing is a:

- (a)  Broker or dealer registered under Section 15 of the Exchange Act.
- (b)  Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c)  Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d)  Investment company registered under Section 8 of the Investment Company Act.
- (e)  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i)  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j)  Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

CUSIP No. 492515101	13G	PAGE 4 OF 5 PAGES
---------------------	-----	-------------------

Item 4.                    Ownership.

- (a)   Amount beneficially owned: 2,266,248 shares
- (b)   Percent of class: 5.2%
- (c)   Number of shares as to which the person has:
  - (i)   Sole power to vote or to direct the vote:  
          2,266,248
  - (ii)   Shared power to vote or to direct the vote: 0
  - (iii)   Sole power to dispose or to direct the disposition  
          of: 2,266,248
  - (iv)   Shared power to dispose or to direct the  
          disposition of: 0

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form SC 13G

- Item 5. Ownership of Five Percent or Less of a Class.
- If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
- Item 6. Ownership of More than Five Percent on Behalf of Another Person.
- Inapplicable.
- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
- Inapplicable.
- Item 8. Identification and Classification of Members of the Group.
- Inapplicable.
- Item 9. Notice of Dissolution of Group.
- Inapplicable.

-----  
CUSIP No. 492515101  
-----

13G

-----  
PAGE 5 OF 5 PAGES  
-----

- Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2007

Chilton Investment Company, LLC

By: /s/ James Steinthal

-----  
Name: James Steinthal  
Title: Managing Director